Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: Relation to side effects, psychosocial function and depression

Michael J. Gitlin, Keith H. Nuechterlein, Jim Mintz, David Fogelson, George Bartzokis, Joseph Ventura, Kenneth Subotnik, Manickam Aravagiri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Rationale: The utility of fluphenazine levels during maintenance treatment of schizophrenia is still unclear. Objectives: This study investigated the relationship between fluphenazine levels and a variety of clinical measures during maintenance treatment of schizophrenia. Methods: Fluphenazine levels, side effects, depression and psychosocial outcome were measured at five time points over approximately 1 year in 59 recent onset schizophrenic patients treated with a maintenance dose of injectable fluphenazine decanoate. Negative symptoms were evaluated at the 1-year endpoint. Results: Fluphenazine levels showed marked intraindividual variability even when measurements were restricted to the second 6 months of treatment, by which time steady state levels should have been achieved. No consistent relationship was found between fluphenazine levels and any of the outcome measures. Conclusions: The results of this study suggest that fluphenazine plasma levels do not routinely add relevant clinical information beyond that of dose in evaluating potential side effects or negative consequences during maintenance treatment with the decanoate form of the medication.

Original languageEnglish (US)
Pages (from-to)350-354
Number of pages5
JournalPsychopharmacology
Volume148
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Fluphenazine
Schizophrenia
Depression
Therapeutics
Decanoates
Outcome Assessment (Health Care)
Injections

Keywords

  • Fluphenazine plasma levels
  • Neuroleptic side effects
  • Neuroleptic treatment
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Gitlin, M. J., Nuechterlein, K. H., Mintz, J., Fogelson, D., Bartzokis, G., Ventura, J., ... Aravagiri, M. (2000). Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: Relation to side effects, psychosocial function and depression. Psychopharmacology, 148(4), 350-354.

Fluphenazine levels during maintenance treatment of recent-onset schizophrenia : Relation to side effects, psychosocial function and depression. / Gitlin, Michael J.; Nuechterlein, Keith H.; Mintz, Jim; Fogelson, David; Bartzokis, George; Ventura, Joseph; Subotnik, Kenneth; Aravagiri, Manickam.

In: Psychopharmacology, Vol. 148, No. 4, 2000, p. 350-354.

Research output: Contribution to journalArticle

Gitlin, MJ, Nuechterlein, KH, Mintz, J, Fogelson, D, Bartzokis, G, Ventura, J, Subotnik, K & Aravagiri, M 2000, 'Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: Relation to side effects, psychosocial function and depression', Psychopharmacology, vol. 148, no. 4, pp. 350-354.
Gitlin, Michael J. ; Nuechterlein, Keith H. ; Mintz, Jim ; Fogelson, David ; Bartzokis, George ; Ventura, Joseph ; Subotnik, Kenneth ; Aravagiri, Manickam. / Fluphenazine levels during maintenance treatment of recent-onset schizophrenia : Relation to side effects, psychosocial function and depression. In: Psychopharmacology. 2000 ; Vol. 148, No. 4. pp. 350-354.
@article{cb52d65172d34247b61cde7e14d31abc,
title = "Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: Relation to side effects, psychosocial function and depression",
abstract = "Rationale: The utility of fluphenazine levels during maintenance treatment of schizophrenia is still unclear. Objectives: This study investigated the relationship between fluphenazine levels and a variety of clinical measures during maintenance treatment of schizophrenia. Methods: Fluphenazine levels, side effects, depression and psychosocial outcome were measured at five time points over approximately 1 year in 59 recent onset schizophrenic patients treated with a maintenance dose of injectable fluphenazine decanoate. Negative symptoms were evaluated at the 1-year endpoint. Results: Fluphenazine levels showed marked intraindividual variability even when measurements were restricted to the second 6 months of treatment, by which time steady state levels should have been achieved. No consistent relationship was found between fluphenazine levels and any of the outcome measures. Conclusions: The results of this study suggest that fluphenazine plasma levels do not routinely add relevant clinical information beyond that of dose in evaluating potential side effects or negative consequences during maintenance treatment with the decanoate form of the medication.",
keywords = "Fluphenazine plasma levels, Neuroleptic side effects, Neuroleptic treatment, Schizophrenia",
author = "Gitlin, {Michael J.} and Nuechterlein, {Keith H.} and Jim Mintz and David Fogelson and George Bartzokis and Joseph Ventura and Kenneth Subotnik and Manickam Aravagiri",
year = "2000",
language = "English (US)",
volume = "148",
pages = "350--354",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Fluphenazine levels during maintenance treatment of recent-onset schizophrenia

T2 - Relation to side effects, psychosocial function and depression

AU - Gitlin, Michael J.

AU - Nuechterlein, Keith H.

AU - Mintz, Jim

AU - Fogelson, David

AU - Bartzokis, George

AU - Ventura, Joseph

AU - Subotnik, Kenneth

AU - Aravagiri, Manickam

PY - 2000

Y1 - 2000

N2 - Rationale: The utility of fluphenazine levels during maintenance treatment of schizophrenia is still unclear. Objectives: This study investigated the relationship between fluphenazine levels and a variety of clinical measures during maintenance treatment of schizophrenia. Methods: Fluphenazine levels, side effects, depression and psychosocial outcome were measured at five time points over approximately 1 year in 59 recent onset schizophrenic patients treated with a maintenance dose of injectable fluphenazine decanoate. Negative symptoms were evaluated at the 1-year endpoint. Results: Fluphenazine levels showed marked intraindividual variability even when measurements were restricted to the second 6 months of treatment, by which time steady state levels should have been achieved. No consistent relationship was found between fluphenazine levels and any of the outcome measures. Conclusions: The results of this study suggest that fluphenazine plasma levels do not routinely add relevant clinical information beyond that of dose in evaluating potential side effects or negative consequences during maintenance treatment with the decanoate form of the medication.

AB - Rationale: The utility of fluphenazine levels during maintenance treatment of schizophrenia is still unclear. Objectives: This study investigated the relationship between fluphenazine levels and a variety of clinical measures during maintenance treatment of schizophrenia. Methods: Fluphenazine levels, side effects, depression and psychosocial outcome were measured at five time points over approximately 1 year in 59 recent onset schizophrenic patients treated with a maintenance dose of injectable fluphenazine decanoate. Negative symptoms were evaluated at the 1-year endpoint. Results: Fluphenazine levels showed marked intraindividual variability even when measurements were restricted to the second 6 months of treatment, by which time steady state levels should have been achieved. No consistent relationship was found between fluphenazine levels and any of the outcome measures. Conclusions: The results of this study suggest that fluphenazine plasma levels do not routinely add relevant clinical information beyond that of dose in evaluating potential side effects or negative consequences during maintenance treatment with the decanoate form of the medication.

KW - Fluphenazine plasma levels

KW - Neuroleptic side effects

KW - Neuroleptic treatment

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0034026898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034026898&partnerID=8YFLogxK

M3 - Article

C2 - 10928306

AN - SCOPUS:0034026898

VL - 148

SP - 350

EP - 354

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -